NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Holdings was planning to go public, but the IPO was withdrawn on Jun 12, 2024.
IPO Price Range
$11.25 - $13.75
Shares Offered
6,000,000
Deal Size
$75.00M
Chart not available yet
Data will show when the stock starts trading.
Market Cap 282.00M
Revenue (ttm) 90,462
Net Income (ttm) -9.83M
Shares Out 22.56M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About NTHI

NeOnc Technologies (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are pa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 8
Stock Exchange NASDAQ
Ticker Symbol NTHI
Full Company Profile

Financial Performance

Financial Statements

News

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

WESTLAKE VILLAGE, Calif., June 26, 2024 (GLOBE NEWSWIRE) --  NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has completed a $18.5 million financing to support the o...

7 days ago - GlobeNewsWire

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases Clinical-Stage Biopharmaceutical Co...

7 weeks ago - GlobeNewsWire

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award SoCal-b...

7 weeks ago - GlobeNewsWire

NeOnc Technologies IPO Registration Document (S-1)

NeOnc Technologies has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC